--- title: "Voyager Therapeutics (VYGR) stock: news and investor profile" url: "https://aibio.space/companies/voyager-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Voyager Therapeutics, Inc. (NASDAQ: VYGR), United States. The directory classifies it as Biotechnology." --- VYGR Voyager Therapeutics, Inc. NASDAQ · United States # Voyager Therapeutics (VYGR) news Listings · 2026-06-10 ## [Voyager Therapeutics holders approve doubling common stock to 240,000,000 shares](https://aibio.space/news/voyager-therapeutics-holders-approve-doubling-common-stock-240-000-000/) Voyager Therapeutics' stockholders approved on June 9, 2026 an increase in authorized common stock from 120,000,000 to 240,000,000 shares, and in total authorized capital stock from 125,000,000 to 245,000,000. The 8-K gives no reason for the increase. ## Latest Voyager Therapeutics news We have not published a story on Voyager Therapeutics yet. When there is news, it will appear here. ## Voyager Therapeutics at a glance - **Ticker**: VYGR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $116.3 million ### Related companies - [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT - [Upstream Bio](https://aibio.space/companies/upstream-bio/) NASDAQ: UPB - [Humacyte](https://aibio.space/companies/humacyte/) NASDAQ: HUMA - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) NASDAQ: XFOR - [Prime Medicine](https://aibio.space/companies/prime-medicine/) NASDAQ: PRME - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Rallybio](https://aibio.space/companies/rallybio/) NASDAQ: RLYB - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) NASDAQ: LABT ### Also on NASDAQ - [Passage Bio](https://aibio.space/companies/passage-bio/) PASG - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) ALNY - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) ESTA - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA - [Immunocore Holdings](https://aibio.space/companies/immunocore/) IMCR - [Lunai Bioworks](https://aibio.space/companies/lunai-bioworks/) LNAI ## What Voyager Therapeutics does Voyager Therapeutics, Inc. is a biotechnology company that aims to leverage human genetics to modify the course of and ultimately cure neurological diseases. Many of its programs derive from its TRACER AAV capsid discovery platform, which identifies capsids with robust blood-brain barrier penetration after intravenous dosing. Its wholly owned pipeline focuses on Alzheimer's disease with two tau-targeting programs. VY1706 is a tau silencing gene therapy that uses an intravenously delivered TRACER capsid containing a vectorized small interfering RNA, and the company expects to submit an investigational new drug application in the second quarter of 2026. VY7523 is an IV-administered anti-tau antibody in a Phase 1 multiple ascending dose trial in early Alzheimer's disease patients, initiated in February 2025. Partnered programs include frataxin and GBA1 gene therapies with Neurocrine Biosciences, a program with Transition Bio on selective small molecules for amyotrophic lateral sclerosis and frontotemporal dementia with TDP-43 pathology, and capsid collaborations with Novartis and Alexion. The text says partnerships have delivered more than $500.0 million in non-dilutive funding to date. | Product or program | What it is | Stage | |---|---|---| | VY1706 | Tau silencing gene therapy for Alzheimer's disease | IND submission anticipated in second quarter of 2026 | | VY7523 | IV-administered anti-tau antibody for Alzheimer's disease | Phase 1 multiple ascending dose trial, initiated February 2025 | | NBIB-’223 (FA Program) | Frataxin gene therapy for Friedreich's ataxia, partnered with Neurocrine | Neurocrine intends to start a trial in second half of 2026, pending IND clearance | | GBA1 Program | GBA1 gene therapy for Gaucher disease and Parkinson's disease, partnered with Neurocrine | | | Transition Bio small molecules | Selective small molecules for ALS and frontotemporal dementia with TDP-43 pathology | | | Voyager NeuroShuttle | Non-viral platform for transporting neurotherapeutics across the blood-brain barrier | | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/vygr-20251231x10k.htm). ## Voyager Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$134.7 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | [$127.4 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | | Net income (loss) | [-$119.7 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | [-$65.0 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | | Cash from operations | [-$132.5 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | [-$15.3 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | | Cash and equivalents | [$65.3 million](https://www.sec.gov/Archives/edgar/data/1640266/000164026626000006/) | [$71.4 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | | Short-term investments | [$131.1 million](https://www.sec.gov/Archives/edgar/data/1640266/000164026626000006/) | [$195.3 million](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $35.8 million, plus short-term investments of $80.6 million, $116.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Voyager Therapeutics What is the ticker symbol of Voyager Therapeutics? Voyager Therapeutics, Inc. trades under the ticker VYGR on NASDAQ. Where is Voyager Therapeutics listed? Voyager Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:VT6; LS:A143XJ. What is the SEC CIK of Voyager Therapeutics? The SEC Central Index Key (CIK) for Voyager Therapeutics, Inc. is 1640266. Its filings are on SEC EDGAR. How many shares does Voyager Therapeutics have outstanding? 61,617,948 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Voyager Therapeutics listed under? Our directory records Voyager Therapeutics, Inc. under United States. What does Voyager Therapeutics do? Our directory classifies Voyager Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Voyager Therapeutics? The ISIN recorded for Voyager Therapeutics, Inc. is US92915B1061. Does aibio.space cover Voyager Therapeutics? aibio.space lists Voyager Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Voyager Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Voyager Therapeutics develop? Voyager Therapeutics, Inc. is a biotechnology company that aims to leverage human genetics to modify the course of and ultimately cure neurological diseases. Many of its programs derive from its TRACER AAV capsid discovery platform, which identifies capsids with robust blood-brain barrier penetration after intravenous dosing. What is VY1706 from Voyager Therapeutics? VY1706: Tau silencing gene therapy for Alzheimer's disease Stage: IND submission anticipated in second quarter of 2026. What is VY7523 from Voyager Therapeutics? VY7523: IV-administered anti-tau antibody for Alzheimer's disease Stage: Phase 1 multiple ascending dose trial, initiated February 2025. Is Voyager Therapeutics profitable? Voyager Therapeutics, Inc. reported a net loss of $119.7 million for the fiscal year ended Dec 31, 2025, and used $132.5 million of cash in operations, per its annual report to the SEC. How much does Voyager Therapeutics spend on research and development? $134.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Voyager Therapeutics have? $116.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Voyager Therapeutics Members talk about Voyager Therapeutics (VYGR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Voyager Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/tm2617230d1_8k.htm) 2. 2026-03-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/vygr-20251231x10k.htm) 3. 2025-03-11 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1640266/000155837025002703/vygr-20241231x10k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VYGR on TradingView](https://www.tradingview.com/symbols/NASDAQ-VYGR/). ## SEC filings and registration - **SEC name**: Voyager Therapeutics, Inc. - **CIK**: 1640266 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: VYGR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Smaller reporting company - **Business address**: 75 HAYDEN AVENUE, LEXINGTON, MA, 02421 - **Phone**: 857-259-5340 - **Shares outstanding**: 61,617,948 as of 2026-07-30 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/d157795d8k.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/vygr-20260806.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1640266/000164026626000006/vygr-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1640266/000110465926082906/tm2620191d1_8k.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/tm2617230d1_8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm) filed 2026-06-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1640266/000110465926057115/vygr-20260507x8k.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1640266/000110465926057097/vygr-20260331x10q.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001640266), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Voyager Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VYGR, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Voyager Therapeutics, Inc. - **Ticker**: VYGR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US92915B1061 - **Other listed symbols**: GETTEX:VT6; LS:A143XJ - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VYGR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/voyager-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Voyager Therapeutics (VYGR) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/voyager-therapeutics/